BOSTON, April 25, 2024 /PRNewswire/ -- Boston Institute
of Biotechnology, LLC (BIB) in collaboration
with BIBo-Biopharma, proudly announces the successful
completion of a groundbreaking 30,000L fermentation run, marking a
significant milestone in biotechnology history.
The endeavor required tremendous effort and expertise, but BIB
and BIBo excelled at every stage, from the initial seed stages to
the critical N-1 stage. Utilizing a production fermenter with a
capacity of 30,000L, we navigated through the process, including
homogenization and IB washes, with exceptional proficiency.
Despite the scale of the operation, our team-maintained control
and performance standards equivalent to those of smaller runs, such
as our 2,000L fermentations. As we await the final yield and titer
results, we anticipate surpassing expectations yet again.
This achievement positions BIB as the first in biotech to
undertake such a large-scale operation for upstream primary
recovery. Not only is this the largest capacity GMP run to date,
but it also sets a new standard for biologics manufacturing.
In an internal release, BIB's senior executive remarked, "We
have successfully completed the first ultra-large 30KL fermentation
for biologics. This accomplishment underscores our dedication to
pushing the boundaries of what is possible, and we are excited to
continue driving innovation in the field."
The P03 facility is a marvel of biopharmaceutical engineering,
boasting the world's largest single-tank and the first
ultra-large-scale production line. Its 24-meter-high building spans
65,000 square meters, housing over 120 kilometers of pipelines, 20
kilometers of clean room air ducts, and nearly 500 kilometers of
cables. With 11 million parts and hundreds of core equipment sets,
each line comprises over 5,000 key procedures. Remarkably, BIBo and
BIB accomplished this complex project in just 18 months, setting a
new standard in biopharmaceutical engineering.
The ultra-large bioreactor is a cornerstone of BIB's commitment
to innovation and efficiency in bioprocessing. Developed as part of
a new generation of systems, it is designed to significantly reduce
costs and accelerate time-to-market, empowering the transformation
of molecules into impactful medicines that benefit patients
worldwide.
For more information, please contact
contactus@bostonbib.com.
Boston Institute of Biotechnology, LLC:
A leading contract development and manufacturing organization
dedicated to advancing healthcare through cutting-edge research,
development, and manufacturing. With a focus on innovation and
excellence, BIB strives to address unmet medical needs and improve
patient outcomes worldwide.
Website: https://bostonbib.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/completion-of-largest-capacity-gmp-run-marks-new-standard-in-biologics-manufacturing-302126682.html
SOURCE Boston Institute of Biotechnology, LLC